Enhancing Injectable Drugs

  • We are a specialty pharmaceutical company focused on developing and commercializing injectable products,
    primarily in the critical care and oncology areas, using the 505(b)(2) regulatory pathway. Our goal is to enter the market before any generics with enhanced versions of existing injectable drugs.

  • Specialty Injectables

    Speciality pharmaceutical company focused on developing and commercializing products for hospital and outpatient infusion clinics.

  • High Value Portfolio of Assets

    Formulation technology and know-how, patent strategy, and market understanding drive product development and Eagle's ability to create value.

  • 21Jan

    Ryanodex® Filing

    Eagle files New Drug Application (NDA) for Ryanodex®, an enhanced formulation of dantrolene for use in malignant hyperthermia.

    Read More
  • 11Feb

    IPO

    Eagle announces Initial Public Offering.

    Read More
  • 23Jul

    Ryanodex® Approval

    FDA Approves Eagle Pharmaceuticals’ Ryanodex® for the Treatment of Malignant Hyperthermia.

    Read More